title: COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-v-FLIP.
abstract: Kaposi's sarcoma herpesvirus (KSHV) latent oncoprotein viral FLICE (FADD-like interferon converting enzyme)-like inhibitory protein (v-FLIP) or K13, a potent activator of NF-κB, has well-established roles in KSHV latency and oncogenesis. KSHV-induced COX-2 represents a novel strategy employed by KSHV to promote latency and inflammation/angiogenesis/invasion. Here, we demonstrate that v-FLIP/K13 promotes tumorigenic effects via the induction of host protein COX-2 and its inflammatory metabolite PGE2 in an NF-κB-dependent manner. In addition to our previous studies demonstrating COX-2/PGE2's role in transcriptional regulation of KSHV latency promoter and latent gene expression, the current study adds to the complexity that though LANA-1 (latency associated nuclear antigen) is utilizing COX-2/PGE2 as critical factors for its transcriptional regulation, it is the v-FLIP/K13 gene in the KSHV latency cluster that maintains continuous COX-2/PGE2 levels in the infected cells. We demonstrate that COX-2 inhibition, via its chemical inhibitors (NS-398 or celecoxib), reduced v-FLIP/K13-mediated NF-κB induction, and extracellular matrix (ECM) interaction-mediated signaling, mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD) levels, and subsequently downregulated detachment-induced apoptosis (anoikis) resistance. vFLIP expression mediated the secretion of cytokines, and spindle cell differentiation activated the phosphorylation of p38, RSK, FAK, Src, Akt and Rac1-GTPase. The COX-2 inhibition in v-FLIP/K13-HMVECs reduced inflammation and invasion/metastasis-related genes, along with reduced anchorage-independent colony formation via modulating 'extrinsic' as well as 'intrinsic' cell death pathways. COX-2 blockade in v-FLIP/K13-HMVEC cells drastically augmented cell death induced by removal of essential growth/survival factors secreted in the microenvironment. Transformed cells obtained from anchorage-independent colonies of COX-2 inhibitor-treated v-FLIP/K13-HMVEC cells expressed lower levels of endothelial-mesenchymal transition genes such as slug, snail and twist, and higher expression of the tumor-suppressor gene, E-cadherin. Taken together, our study provides strong evidences that FDA-approved COX-2 inhibitors have great potential in blocking tumorigenic events linked to KSHV's oncogenic protein v-FLIP/K13.
authors.affiliation: Department of Microbiology and Immunology, H.M. Bligh Cancer Research Laboratories, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
authors.forename: N
authors.initials: N
authors.lastname: Sharma-Walia
authors.forename: K
authors.initials: K
authors.lastname: Patel
authors.forename: K
authors.initials: K
authors.lastname: Chandran
authors.forename: A
authors.initials: A
authors.lastname: Marginean
authors.forename: V
authors.initials: V
authors.lastname: Bottero
authors.forename: N
authors.initials: N
authors.lastname: Kerur
authors.forename: A G
authors.initials: AG
authors.lastname: Paul
references.citation: J Exp Med. 2007 Nov 26;204(12):2935-48
references.pmid: 17984306
references.citation: Cancer Res. 2005 Dec 15;65(24):11230-5
references.pmid: 16357123
references.citation: PLoS Pathog. 2010 Feb 12;6(2):e1000777
references.pmid: 20169190
references.citation: Cancer Lett. 2004 May 10;208(1):115-22
references.pmid: 15105053
references.citation: Dev Biol. 1999 Aug 1;212(1):243-54
references.pmid: 10419699
references.citation: J Biol Chem. 2002 Apr 19;277(16):13745-51
references.pmid: 11830587
references.citation: Endothelium. 2005 Jul-Aug;12(4):193-200
references.pmid: 16162442
references.citation: J Med Chem. 1997 Apr 25;40(9):1347-65
references.pmid: 9135032
references.citation: Oncogene. 2002 Sep 5;21(39):6113-22
references.pmid: 12203123
references.citation: Nat Med. 1995 Dec;1(12):1274-8
references.pmid: 7489408
references.citation: Oncogene. 2008 Apr 17;27(18):2656-60
references.pmid: 17968315
references.citation: Cancer Res. 2010 May 1;70(9):3697-708
references.pmid: 20388794
references.citation: PLoS One. 2011;6(9):e24379
references.pmid: 21980345
references.citation: Virology. 2004 Oct 10;328(1):7-18
references.pmid: 15380353
references.citation: Cancer Res. 2007 May 1;67(9):4042-51
references.pmid: 17483315
references.citation: JAMA. 2002 Jan 9;287(2):221-5
references.pmid: 11779265
references.citation: J Virol. 2010 Dec;84(24):12733-53
references.pmid: 20943963
references.citation: J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80
references.pmid: 15572759
references.citation: Cancer Treat Res. 2007;133:69-127
references.pmid: 17672038
references.citation: J Virol. 2009 Mar;83(5):2140-53
references.pmid: 19091861
references.citation: Cancer Res. 2000 Jan 15;60(2):293-7
references.pmid: 10667579
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404
references.pmid: 15190178
references.citation: Mol Biol Cell. 1993 Sep;4(9):953-61
references.pmid: 8257797
references.citation: Mol Biol Cell. 2000 Mar;11(3):1047-60
references.pmid: 10712519
references.citation: Nat Rev Cancer. 2005 Jan;5(1):51-63
references.pmid: 15630415
references.citation: Oncogene. 1999 Jan 14;18(2):407-15
references.pmid: 9927197
references.citation: J Cell Sci. 2008 Feb 15;121(Pt 4):450-7
references.pmid: 18211958
references.citation: Oncogene. 1999 Oct 14;18(42):5738-46
references.pmid: 10523854
references.citation: Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
references.pmid: 18097445
references.citation: Future Oncol. 2006 Dec;2(6):697-704
references.pmid: 17155896
references.citation: N Engl J Med. 1995 May 4;332(18):1186-91
references.pmid: 7700311
references.citation: Cell Death Differ. 2009 Mar;16(3):368-77
references.pmid: 18846109
references.citation: J Virol. 1999 Aug;73(8):6892-902
references.pmid: 10400787
references.citation: Cell. 2004 Jan 23;116(2):167-79
references.pmid: 14744429
references.citation: J Virol. 2004 Apr;78(8):4207-23
references.pmid: 15047836
references.citation: Nat Rev Cancer. 2002 May;2(5):373-82
references.pmid: 12044013
references.citation: BMC Med Genomics. 2009 Aug 06;2:50
references.pmid: 19660139
references.citation: Semin Cancer Biol. 1999 Jun;9(3):165-74
references.pmid: 10343068
references.citation: Cell. 2002 Apr;109 Suppl:S81-96
references.pmid: 11983155
references.citation: J Biol Chem. 2000 Aug 4;275(31):23627-35
references.pmid: 10816557
references.citation: J Biol Chem. 2003 Feb 14;278(7):4660-7
references.pmid: 12468545
references.citation: Oncogene. 2006 May 4;25(19):2717-26
references.pmid: 16418726
references.citation: Curr Top Pathol. 1999;93:75-85
references.pmid: 10339900
references.citation: J Virol. 2006 Jul;80(13):6534-52
references.pmid: 16775340
references.citation: J Cell Biol. 2009 Apr 20;185(2):279-90
references.pmid: 19380879
references.citation: Cell. 1992 Apr 3;69(1):11-25
references.pmid: 1555235
references.citation: Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30
references.pmid: 17512904
references.citation: Curr Opin Cell Biol. 1997 Oct;9(5):701-6
references.pmid: 9330874
references.citation: Int J Cancer. 2006 May 15;118(10):2381-9
references.pmid: 16353145
references.citation: Cancer Res. 2006 May 15;66(10):5338-45
references.pmid: 16707460
references.citation: J Virol. 2001 Jun;75(12):5614-26
references.pmid: 11356969
references.citation: Mol Cell. 2001 Sep;8(3):705-11
references.pmid: 11583631
references.citation: J Virol. 2006 Jul;80(14):7179-85
references.pmid: 16809323